ANIP Q3 2025 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$228M+53.6% YoY

Gross Profit

$112M49.1% margin

Operating Income

$23M10.0% margin

Net Income

$24M10.6% margin

EPS (Diluted)

$1.13

QoQ Revenue Growth

+7.8%

Cash Flow

Operating Cash Flow

$44M

Free Cash Flow

$38M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$902M

Stockholders' Equity

$506M

Cash & Equivalents

$263M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$228M	$148M	+53.6%
Gross Profit	$112M	$85M	+31.1%
Operating Income	$23M	-$21M	+211.3%
Net Income	$24M	-$24M	+199.9%

Revenue Segments

Sales of rare disease pharmaceutical products

$118M52%

Total Sales of Generics and Other

$99M43%

Sales of Established Brands

$11M5%